BioData World Congress

We introduce to you the most important event in Big Data and Genomics. We have developed an event with the one goal of driving precision medicine into the clinic in the most streamlined and effective way possible:
-Bringing together clinicians, big pharma, biotech institutions, policy makers, visionary academics and data leaders to facilitate partnerships and drive progress.
-Reviewing game changing innovation, roadblocks, and critical success factors in the practical application of big data.
-Understanding how big data is driving developments in personalised medicine.

Precision medicine is only attainable through bringing together the world’s principal decision makers involved in this multidisciplinary effort to one platform.

This is why the world’s leading international institutions have partnered to make this a reality. These institutions include: The Wellcome Trust Sanger Institute, EMBL-EBI, Global Alliance for Genomics and Health, Babraham Institute, ABPI, Pharmacogenetics and Stratified Medicine Network, BIA, Pistoia Alliance, Cancer Research UK, The Farr Institute and the Francis Crick Institute.

Price
Vendor Package: GBP 1000
Pharma/Biotech Package: GBP 600
Academics Package: GBP 325

Speakers: Ewan Birney Associate Director EMBL-EBI, Rolf Apweiler Associate Director EMBL-EBI, Tim Hubbard Head of Bioinformatics Genomics England, Sue Hill CSO NHS, Paul Workman CEO and President The Institute of Cancer Research, Sir John Burn Non-executive director NHS, Andrew Morris Director Farr Institute, Iris Grossman Vice President Head of Personalized & Predictive Medicine and Big Data Analytics Teva Pharmaceuticals, Julia Wilson Associate Director Wellcome Trust Sanger Institute, Peter Frommolt Head of Bioinformatics Facility Universitaet Zu Koeln, Mark Lawler Chair in Translational Cancer Genomics Queens University Belfast, Ruth March VP and Head Personalised Healthcare & Biomarkers AstraZeneca, Rowena Sharpe Head of Precision Medicine Cancer Research UK, Tosin Sule Senior Business Analyst Stratified Medicine Cancer Research UK, Kerina Jones Director Farr Institute SAIL, Clair Turnball Clinical lead Genomics England, David Smith Professor of Laboratory Medicine And Pathology Mayo Clinic, Miles Carrol Deputy Director Public Health England, Edward Oakeley Head of Next Generation Sequencing Novartis, Denis Horgan Executive Director European Alliance for Personalised Medicine, Eleftheria Zeggini Group Leader Wellcome Trust Sanger Institute, Irene Norstedt Head of Unit Personalised Medicine European Commission, Carla Deakin Associate Director - Diagnostics Assessment Programme NICE, Olga Golubnitschaja Secretary-General EPMA, Sir Munir Pirmohamed Chair of Pharmacogenetics NHS, Colin Cooper Professor of Cancer Genetics UEA, Timothy Stitt Head of Scientific Computing TGAC, Stuart Bayliss Project Manager Centre for Genomic Medicine Manchester Centre for Genomics, Karen Temple Professor of Medical Genetics Director of Human Development and Health Honorary Consultant in Clinical Genetics University of Southampton, Kathy Niakan Group Leader Crick Institute, Dr Phil Hammond Medical Correspondent Author and Comedian Private Eye, Stephan Beck Professor of Medical Genetics UCL, Jan Kuentze Head of Data Science Application services Project lead for implementing new biomedical data and workflow mgmt framework Roche, John Taysom Board Member & Non Executive Director Web Science Trust Senior Fellow Advanced Leadership Initiative Harvard University, Fanny Decarpentrie Research Fellow Crick Institute, Andrew Futreal Chair of Genomic Medicine Anderson Cancer Center, Gunaretnam (Guna) Rajagopal VP Global Head – Computational Sciences Discovery Sciences Janssen Research & Development A Johnson & Johnson Company, Mathew Woodwark Director of Research Bioinformatics MedImmune, Mr John Wise Executive Director Pistoia Alliance, Patrick Harrison Head of Physiology University College Cork, Matt Cooper Business Development and Marketing Director NIHR, Laura Clarke Data Management EMBL-EBI, Sajan Khosla Head Health Informatic AstraZeneca, Athula Herath Statistical Director Research Statistics Translational Science MedImmune Biotech Unit of AstraZeneca, Prof Anneke Lucassen Consultant in Clinical Genetics University of Southampton, Prof. Dr. Christof von Kalle Managing Director of the NCT (National Center for Tumor Diseases) Head of Translational Oncology DKZF, Anna Middleton Principal Social Scientist Sanger Institute, Hazel Jones Head of Combination Therapies CRUK, Michael Rebhan Senior Investigator Novartis, Philippe Sanseau Head Computational Biology GSK R&D, Claudio Carini Global Head Clinical Immunology and Biomarkers Pfizer, Paul Peter Tak Senior Vice President of Research and Development Pipeline and Chief Immunology Officer GSK, Susanne Hollmann CHARM, Andreas Kremer CHARM, Martin Golebiewski CHARM, Shahid Hanif Head of Health Data and Outcomes A.B.P.I., Morten Sogaard Vice President and Head of Enterprise Scientific Technology Operations Pfizer, Andrew Roddam Vice President & Global Head Epidemiology GSK, Pall Jonsson Senior Scientific Adviser NICE, David Oppenheim Genomics & Biomedical Data Lead NHS England, Simon Hollingsworth Executive Director Stratified Medicine Studies (Oncology) AstraZeneca

Time: On Wednesday October 26, 2016 at 8:00 am and ends Thursday October 27, 2016 at 5:00 pm